Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Hospital-Acquired Lung infection Treatment with novel inhaled Anti-Microbial Resistance Beta-lactamase inhibitors (HALT-AMR)
| Reference number | 2025-01839 |
| Coordinator | CTC Clinical Trial Consultants AB |
| Funding from Vinnova | SEK 4 998 587 |
| Project duration | October 2025 - October 2028 |
| Status | Ongoing |
| Venture | Eurostars |
Last updated 1 September 2025
Reference number 2025-01839
